2014
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.7448/IAS.17.4.19622
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25394126
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/isbn/1758-2652
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7A2A796D55924
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
L. Merz et al., « Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. », Serveur académique Lausannois, ID : 10.7448/IAS.17.4.19622
BACKGROUND: Since the advent of combined antiretroviral therapy (ART), the incidence of non-AIDS-defining cancers (non-ADCs) among HIV-positive patients is rising. We previously described HIV testing rates of 0.1%. Phase II of the IBITOP study is now underway to explore barriers to HIV screening among oncologists and patients following the updated national HIV testing guidelines which recommend testing in non-ADC patients undergoing chemotherapy.